ArticleTransfusion2022
Antibodies against biotin-labeled red blood cells can shorten posttransfusion survival.
Article in Transfusion, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06788080 (Optimization of Biotinylation Protocol for Next Generation Studies of Red Blood Cell Survival and Function After Transfusion), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimization of Biotinylation Protocol for Next Generation Studies of Red Blood Cell Survival and Function After Transfusion
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- The Immunology of Transfusion Medicine: Past, Present, and Future.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Optimization of biotinylation protocol for next generation studies of red blood cell survival after transfusion.Transfusion · 2025Article
- A novel acridine flow cytometry marker to track post-transfusion amustaline/glutathione pathogen-reduced red blood cell survival in sickle cell disease patients.Transfusion · 2025Article
- Harnessing the potential of red blood cells in immunotherapy.Human immunology · 2024Review
- Post-transfusion biotin-labeled red blood cell survival studies in pediatric sickle cell disease with antibodies of uncertain significance.Transfusion · 2024Article
- Relationship between sheep feces scores and gastrointestinal microorganisms and their effects on growth traits and blood indicators.Frontiers in microbiology · 2024Article
- The Development and Consequences of Red Blood Cell Alloimmunization.Annual review of pathology · 2023Review
- Advances in Microfluidics for Single Red Blood Cell Analysis.Biosensors · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundIn hematologic and transfusion medicine research, measurement of red blood cell (RBC) in vivo kinetics must be safe and accurate. Recent reports indicate use of biotin-labeled RBC (BioRBC) to determine red cell survival (RCS) offers substantial advantages over STUDY DESIGN AND
methodsTo investigate the causes and consequences of BioRBC immunization, we reexposed three previously immunized adults to BioRBC and evaluated the safety, antibody emergence, and RCS of BioRBC.
resultsBioRBC re-exposure caused an anamnestic increase of plasma BioRBC antibodies at 5-7 days; all were subclass IgG DISCUSSION: We conclude re-exposure of immunized subjects to BioRBC can induce anamnestic antibody response that can cause an underestimation of RCS. To minimize chances of antibody induction and underestimation of RCS, we recommend an initial BioRBC exposure volume of ≤10 mL and label densities of ≤18 μg/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.